Background
Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection.
Methods
Microarrays from 434 patients randomized to chemotherapy in the ESPAC-3 trial (plus controls from ESPAC-1/3) were stained with the 10D7G2 anti-hENT1 antibody. Patients were classified as having high hENT1 expression if the mean H score for their cores was above the overall median H score (48). High and low hENT1-expressing groups were compared using Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models. All statistical tests were two-sided.
Results
Three hundred eighty patients (87.6%) and 1808 cores were suitable and included in the final analysis. Median overall survival for gemcitabine-treated patients (n = 176) was 23. 
Conclusions
Subject to prospective validation, gemcitabine should not be used for patients with low tumor hENT1 expression.
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Pancreatic ductal adenocarcinoma is a leading cause of cancer death and is characterized by early micrometastatic disease (1) . most patients have advanced noncurable disease, but survival can be prolonged with mono or combination chemotherapy (2,3) using 5-fluorouracil (5Fu)-based regimens including FoLFIrINoX (4) or using gemcitabine monotherapy or couplets such as gemcitabine with nab-paclitaxel (5) . Surgical resection, which is possible in 15% to 20% of patients, can provide 5-year survival in only 10% of these (3) . Although the greatly improved survival advantage for adjuvant chemotherapy is now well established (6) (7) (8) (9) (10) , there is no randomized phase III clinical trial supporting evidence for the use of adjuvant chemoradiotherapy over systemic chemotherapy alone (3, (11) (12) (13) . Although the growing understanding of the molecular pathology of pancreatic cancer may well lead to more targeted therapies (14, 15) , there is now considerable opportunity for improved outcomes based on current therapies through the stratified medicines approach using appropriate response biomarkers (3, 15) . A promising biomarker is the human equilibrative nucleoside transporter 1 (heNt1), which permits the bidirectional passage into cells of pyrimidine nucleosides such as gemcitabine capecitabine and 5Fu (16, 17) . the original clinical study, which was undertaken using stored tissue from 21 patients with advanced pancreatic cancer treated with gemcitabine, showed that cancer tissue from patients with greater heNt1 expression by immunohistochemistry had a longer survival (17) . Subsequent studies have provided encouraging but not convincing evidence because they have been mostly retrospective and nonrandomized series (18, (20) (21) (22) (23) (24) (25) , with mixed advanced and adjuvant cases (18) , based on neoadjuvant (24, 25) or adjuvant chemoradiotherapy (18) (19) (20) (21) (22) or using combination regimens such as gemcitabine with S-1, which is a 5Fu-prodrug (23) . None of these latter studies truly tested gemcitabine monotherapy in a defined group of patients (18) (19) (20) (21) (22) (23) (24) (25) . moreover patients with a better performance status are more likely to receive gemcitabine treatment, whereas those with poor performance are more likely to receive no or only limited treatment. thus it is not possible to discriminate between a therapeutic predictive effect and a disease prognostic effect for heNt1 expression.
there is, however, considerable opportunity to minimize biases in biomarker development for pancreatic cancer by using clinical data and cancer tissue collected from prospective, randomized controlled trials conducted by the european Study Group for Pancreatic Cancer (eSPAC) (trial registration clinicaltrials.gov: NCt00058201). eSPAC-1 showed that adjuvant chemotherapy using 5Fu/folinic acid improved overall survival but that adjuvant chemoradiotherapy did not (6, 7) . eSPAC-3(v2) demonstrated that adjuvant gemcitabine was not superior to 5Fu/folinic acid (9) . therefore our main aim was to determine whether tumor heNt1 levels would help predict overall survival for patients receiving gemcitabine compared with patients receiving 5Fu.
Methods
Study Design the translational eSPAC-t studies received ethical committee approval for characterization of tumor markers for chemotherapy from the Liverpool (Adult) research ethics Committee (07/ h1005/87). use of Good Clinical Practice standard operating procedures (26) ensures a full audit trail and prevents access to outcome data by pathologists and laboratory researchers. After resection for pancreatic ductal adenocarcinoma, patients in the eSPAC-1 (6,7) 2 × 2 factorial trial were randomized either to receive chemoradiotherapy or not and also to receive chemotherapy using 5Fu and folinic acid or not. In the eSPAC-3 study (9), patients were randomized to observation or to receive either 5Fu with folinic acid, as in the eSPAC-1 trial, or gemcitabine. once the definitive results of eSPAC-1 were known (7), the observation arm was removed, and the trial was renamed eSPAC-3(v2) (9) . Both studies were analyzed on an intention-to-treat basis, but for the eSPAC-t study, patients in the treatment arms were selected for inclusion only if treatment was actually received. All patients provided written informed consent. this study was conducted and reported in accordance with the remArK criteria (27) .
Tissue Microarray Manufacture the arrays were manufactured using standard operating procedures conducted to Laboratory Good Clinical Practice. the treatment arrays contained cores from patients entirely from eSPAC-3(v2) randomized to either 5Fu/folinic acid or to gemcitabine. the observation array contained cores from both eSPAC-1 and eSPAC-3 because of the paucity of samples from patients truly randomized to observation. Although fixation protocols for formalin-fixed paraffinembedded tissue blocks varied across centers, they were standardized for each center with no evidence for center-or country-specific bias in heNt1 staining (see Supplementary table 1, available online). Cores were taken from tumor regions identified by an experienced pancreatic pathologist (F. Campbell) using hematoxylin and eosinstained sections. tissue microarrays were prepared with two cores from each block, with four to eight cores arrayed for each patient.
each of the treatment eSPAC-3(v2) arrays had two cores from 88 patients, whereas the observation array had four cores from 31 patients. For all arrays, control cores, comprising three cores each of colon, kidney, liver, normal pancreas, and chronic pancreatitis, were arranged in a fence around the test samples.
Antibody Validation
the mouse monoclonal anti-heNt1 antibody 10D7G2 was used (17, 28) . Western blotting revealed a series of bands between 30 KDa and 70K Da in the pancreatic cancer cell lines Panc-1, Suit-2, miaPaCa, and BxPC3. Immunoblotting confirmed that 10D7G2 detected a full heNt1 sequence GSt-tagged recombinant protein (SLC29A1 human recombinant protein; Abnova taiwan) at concentrations of 3 0ng to 200 ng per lane. mass spectrometry (triple toF-5600; AB Sciex, Warrington, uK) of 10D7G2 immunoprecipitate from polyacrylamide gel bands prepared from Panc-1 and miaPaCa cells revealed a single heNt1 peptide (AGKeeSGVSVSNSQPtNeShSIK) in the 50 KDa band, which was not seen with the control immunoprecipitate (beads but no antibody). Clean-up of the antibody was required using preabsorption to reduce background and improve specificity before Western blotting. Preabsorption was performed using 5 mL of 1:500 dilution of 10D7G2 in 3% bovine serum albumin in phosphate-buffered saline/0.1% tween. A 10% tris glycine gel was run with 20 µg total protein per well from BxPC3, Suit2 Panc1, miaPaCa, and heLa cell lines and transferred to a polyvinylidene fluoride membrane. the membrane was blocked in 3% bovine serum albumin diluted in phosphate-buffered saline/0.1% tween.
Immunoblotting was performed at room temperature with agitation for 1 hour. this removed some of the nonspecific binding of the antibody. the antibody solution was then decanted and used to immunoblot polyvinylidene fluoride membranes containing lysate from knockdown experiments and the immunoprecipitation lysate.
heLa wild-type cells, heLa with heNt1 knockdown, and heLa cells engineered to overexpress heNt1 were grown in 2 × t150 flasks to confluency. the cells were pelleted by centrifugation and fixed in 10% neutral buffered formalin overnight. Cells were then mixed in a 1:1 ratio with 4% agar and set in a mold. the resulting cell pellet was formalin fixed and embedded in paraffin. Five micrometer sections were prepared on Superfrost Plus slides. A 1:2 dilution of 10D7G2 antibody in 0.05mol/L tris-hCl buffer ph 7.2 was used for immunocytochemistry. heNt1 expression in heLa cells showed strong membrane staining along with some cytoplasmic and nuclear staining. heNt1 knockdown by small interfering rNA reduced membrane and cytoplasmic staining in heLa cells, whereas heNt1-overexpressing heLa cells resulted in increased membrane and cytoplasmic staining.
Immunohistochemistry the heNt1 10D7G2 antibody was diluted 1:2 in 0.05 mol/L trishCl buffer ph 7.2 for immunohistochemistry on 5-µm sections of the tissue microarrays. After deparaffinization and hydration of sections, antigens were retrieved by heat treatment in citrate buffer ph 6.0. Sections were treated with peroxidase block. Slides were incubated with the primary antibody in tris buffer (as above) at 4 o C overnight. Immunostaining was performed by the avidin-biotin peroxidase complex technique (enVision System; Dako, ely, uK). Negative controls were incubated with buffer alone in place of primary antibody.
Cores were scored by a specialist pancreas histopathologist (F. Campbell) assisted by a technician (e. Garner) to record the findings for each core. F. Campbell was blinded to treatment group when scoring. Both F. Campbell and e. Garner were blinded to patient outcomes throughout the study. the intensity of cytoplasmic and membrane staining in tumor cells was ranked from 1 to 3. Lymphocyte staining was taken as an internal positive control (9) . h scores were produced for each core by multiplying intensity score by the percentage of tumor cells stained, and a mean h score was calculated for each patient based on four to eight cores (Supplementary Figure 1, available online) .
Statistical Analysis the largest previous study had reported an unadjusted hazard ratio (hr) in favor of heNt1 levels predicting response to adjuvant therapy (albeit a mix of adjuvant chemotherapy and chemoradiotherapy regimens that included gemcitabine at some point) of 0.43 (95% confidence interval [CI] = 0.29 to 0.63; n = 243) (21) . A more conservative power calculation was used in our study based on 175 patients with 137 deaths within each treatment arm, which, assuming a split ratio of 1:1 of high to low heNt1 expression, would detect a hazard ratio of 0.62 between the two levels of expression, for a statistical significance level of .05 at 80% power.
All analyses were carried out using SAS version 9.2 software (SAS Institute, Cary, NC). Survival from date of randomization was analyzed by the method of Kaplan-meier (29) , with differences between groups assessed using the mantel-Cox log rank test with multiple comparisons adjusted by the method of tukey-Kramer. recurrence-free survival was time to recurrence as assessed by computerised tomography or time to death. univariate and multivariable analyses were carried out using Cox proportional hazards. the checking of proportionality and model fit was carried out using plots of log(-log(survival)) against log(survival time) and martingale and deviance residual plots.
A log transformation was also made on the h scores because of the skewed data distribution and where zero values were given a notional value of 1 to allow the use of logarithms. Variables included in the analyses were sex and country but not ethnicity because this information had not been collected. All statistical tests were two-sided result Patients and Tissue Samples twelve tissue microarrays representing 202 gemcitabine-treated patients, 201 patients treated with 5Fu/folinic acid, and 31 true resection only patients, were chosen for this study (Figure 1 ). three hundred eighty patients (87.6%) and 1808 cores were included in the final analysis, and the demographic, surgery, and pathology features of the patients included are shown in table 1. hENT1 Staining the overall h score median was 48, interquartile range (IQr) was 10 to 80, and range was 0 to 210. the median h score was 42 (IQr = 3-69) for the 5Fu/folinic acid group, 50 (IQr = 24-93) for the gemcitabine group, and 86 (IQr = 40-101) for the observation group. using the overall median h score of 48 as the threshold, in the gemcitabine group (n = 176), there were 146 (83.0%) deaths with 74 (50.7%) above the threshold. In the 5Fu/folinic acid group (n = 176), there were 139 (79.0%) deaths with 60 (43.2%) above the threshold. In the observation group (n = 28), there were 23 (82.1%) deaths with 18 (78.3%) above the threshold. Contingency testing of heNt1 levels with clinical and tumor characteristics (table 2) did not reveal any statistically significant associations except that a younger age might be associated with higher heNt1 tumor expression (crude P = .02), although this was not statistically significant after correction for multiple testing.
Overall Survival Analysis the median overall survival for the gemcitabine-treated patients was 23.4 (95% CI = 18.3 to 26.0) months compared with 23.5 (95% CI = 19.8 to 27.3) months for the patients treated with 5Fu/folinic acid (χ 2 1 = 0.241; P = .62). the median survival for the patients treated with gemcitabine with low heNt1 levels was 17.1 (95% CI = 14.3 to 23.8) months compared with 26.2 (95% CI = 21.2 to 31.4) months for those with high heNt1 levels (χ 2 1 = 9.87; P = .002), with hazard ratio of 0.60 (95% CI = 0.43 to 0.83) for high expressers compared with low expressers (Figure 2 ). thus our primary null-hypothesis was rejected, indicating a difference of 9.1 months in median survival for high and low heNt1 expressers in gemcitabine-treated patients.
the median survival in patients treated with 5Fu/folinic acid was 25.6 (95% CI = 20.1 to 27.9) months for those with low heNt1 levels and 21.9 (95% CI = 16.0 to 28.3) months for those with high heNt1 levels (χ 2 1 = 0.83; P = .36), with a hazard ratio of 1.17 (95% CI = 0.84 to 1.64).
Survival for the pure observation patients did not differ by heNt1 expression regardless of whether the overall median h score (χ 2 1 = 0.37; P = .54) or the median h score just for patients in the observation group was used as the threshold (Supplementary Figure 2, available online) .
A further analysis was also carried out using a Cox proportional hazards model with log(heNt1) as a covariable for each chemotherapy arm. For the gemcitabine arm, log(heNt1) was a statistically significant covariable (P = .03), with hazard ratio of 0.80 per 10 units of heNt1. For the 5Fu arm, log(heNt1) was not a statistically significant covariable (P = .90). univariate analysis of the resection margin status, lymph node status, tumor stage, local invasion, and maximum tumor diameter all showed the expected statistically significant association with survival. Differences in survival with local invasion, diabetes mellitus, sex, and age did not reach statistical significance. tumor grade, smoking, and heNt1 expression were only shown to be statistically significantly associated with survival in patients randomized to gemcitabine (table 3) . multivariable analysis of survival to allow for resection margin status, lymph node status, tumor grade, sex, and smoking (table 4) was statistically significant for the heNt1 expression in the gemcitabine group (Wald χ 2 = 9.16; P = .003) but not for the 5Fu/folinic acid group (Wald χ 2 = 1.22; P = .27). Pairwise comparisons of all variations of heNt1 level and treatment arms showed that only in the gemcitabine arm was high heNt1 statistically significantly associated with survival (χ 2 = 8.62; P = .02) (Supplementary table 4, available online) . A series of h score sensitivity analyses was undertaken, including removing the middle 15 and 30 percentiles without affecting the principal conclusion ( Supplementary Figures 3 and 4 , available online). Similarlyl taking only the top and bottom 33% of each treatment group (Supplementary Figure 5 , available online) and normalization of the scores for each array (Supplementary Figure 6 , available online) gave the same trends.
Recurrence-Free Survival recurrence-free survival curves mirrored the findings for overall survival (Supplementary Figure 7, available online) . median recurrencefree survival for gemcitabine-treated patients was 11.1 (95% CI = 8.8 ) and hENT1 expression levels (high = mean H score ≥48; low = mean H score <48). All groups and the number of at risk individuals are shown in the top graph, and below the data are separated out for ease of viewing of pairwise comparisons. All statistical tests were log-rank analyses using two-sided χ 2 tests. CI = confidence interval.
to 13.8) months for those with low heNt1 levels and 14.3 (95% CI = 11.6 to 16.6) months for those with high heNt1 levels. For the gemcitabine-treated patients, there was a statistically significant difference in recurrence-free survival between high and low heNt1 expressers (χ 2 = 7.45′ P = .006). median recurrence-free survival for 5Fu-treated patients was 12.5 months (95% CI = 9.7 to 17.8) months for those with low heNt1 expression and 12.8 (95% CI = 10.3 to 15.9) months for those with high heNt1 expression (χ 2 = 1.43; P = .23).
Discussion
this is the first study to test heNt1 expression levels in an unbiased group of patients that were given gemcitabine monotherapy in the identical clinical setting by using tissues and clinical data from the treatment arms used in the same randomized trial. thus we only included treated patients from the adjuvant eSPAC3(v2) trial (9) . Because we wished also to explore analysis in a pure control group specifically randomized to no adjuvant treatment, this meant combining the observation arms from the eSPAC-1 (6,7) and eSPAC-3 (9) trials. Although the resultant number of cases investigated was small, there was no evidence to support heNt1 expression levels per se as indicative of overall survival. taken together, the results of this study have provided powerful evidence that adjuvant gemcitabine should not be used after resection for patients with low tumor heNt1 expression, the alternative being 5Fu-based regimens, and by implication vice versa. the bias of nonrandomized studies makes it impossible to separate a predictive therapeutic-specific effect from a disease prognostic-specific effect. As well as using patients from retrospective uncontrolled cohorts, methodological considerations may have contributed to the variability of previously published studies. Differences in heNt1 rNA transcript levels between studies can be difficult to interpret given the variances in tissue collection, storage, retrieval, and analytical techniques; in one study showed that higher heNt1 transcript levels were associated with longer survival (18) , but in another study heNt1 transcript levels appeared to be prognostic irrespective of gemcitabine use (20) . three studies of adjuvant gemcitabine and chemoradiation that showed a survival benefit for higher heNt1 levels used the 10D7G2 monoclonal murine antibody (19, 20, 21) , whereas the study that showed an opposite benefit with low heNt1 expression used a Sigma-Aldrich polyclonal antibody (23) and the adjuvant study of gemcitabine and S-1 used an Abnova polyclonal rabbit antibody (22) . on the other hand these differences are just as likely to be due to stage mix and patient selection.
It is not entirely certain as to how heNt1 expression levels in resected specimens may relate to the residual micrometastases responsible for recurrence after treatment (1) . one potential explanation for the interaction between heNt1 expression levels and benefit from specific therapies is that heNt1 has a far greater affinity for nucleosides such as gemcitabine than for nucleobases such as 5Fu (30, 31) . Also other proteins, including the human organic anion transporter 2 (32) or heNt2 (33), may more readily mediate 5Fu uptake. the one previous randomized study in which heNt1 expression was explored was in a small subset of the rtoG-9704 trial, essentially an adjuvant chemoradiotherapy trial, with patients randomized to short courses of 5Fu or gemcitabine both before and after chemoradiotherapy and using 5Fu as the radiosensitizer in both arms (19) . A high level of heNt1 expression was associated with a survival benefit compared with low heNt1 levels in the gemcitabine 5Fu-chemoradiotherapy-treated group. Interpretation is undermined, however, because the survival benefit of adjuvant chemoradiotherapy remains unproven in pancreatic cancer (3, (11) (12) (13) .
the recently reported randomized phase II advanced pancreatic cancer LeAP trial of a membrane permeable form of gemcitabine (Co-101) failed to meet its primary endpoint (34) . In this trial, no survival advantage in gemcitabine-treated patients was seen for high heNt1 expression determined by immunohistochemistry using the SP120 rabbit monoclonal antibody. this SP120 antibody was only previously tested in a small subset of the 5Fu-based chemoradiation rtoG-9704 trial using primary tumor tissue, whereas in the LeAP trial heNt1 expression appears to have been largely determined in metastatic tissue. It remains uncertain whether heNt1 expression levels can provide similar predictive therapeutic information between adjuvant gemcitabine with 5Fu-chemoradiotherapy in the post-resection setting on the one hand and palliative gemcitabine in the advanced and metastatic setting on the other hand. the performance of the SP120 antibody might also be in question, but it is now not possible to compare this rabbit antibody with the 10D7G2 murine antibody because the former is no longer available. overall then it is unclear whether the SP120 antibody was adequately validated by examining heNt1 expression levels in metastatic pancreas cancer tissues in patients who had received gemcitabine as the only therapy before testing in the LeAP trial. In contrast heNt1 expression using the 10D7G2 antibody has been tested in patients who have received gemcitabine monotherapy in both the advanced (17) and now the adjuvant setting with consistent results. our study 
